Tebuzate en es it fr

Tebuzate Brand names, Tebuzate Analogs

Tebuzate Brand Names Mixture

  • No information avaliable

Tebuzate Chemical_Formula


Tebuzate RX_link


Tebuzate fda sheet

Tebuzate msds (material safety sheet)

Tebuzate Synthesis Reference

No information avaliable

Tebuzate Molecular Weight

192.258 g/mol

Tebuzate Melting Point

246-266 oC

Tebuzate H2O Solubility

1.07E+004 mg/L

Tebuzate State


Tebuzate LogP


Tebuzate Dosage Forms

400 mg and 600 mg tablets for oral administration

Tebuzate Indication

For the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening.

Tebuzate Pharmacology

Tocainide is a primary amine analog of lidocaine with antiarrhythmic properties useful in the treatment of ventricular arrhythmias. Tocainide, like lidocaine, produces dose dependent decreases in sodium and potassium conductance, thereby decreasing the excitability of myocardial cells. In experimental animal models, the dose-related depression of sodium current is more pronounced in ischemic tissue than in normal tissue. Tocainide is a Class I antiarrhythmic compound with electrophysiologic properties in man similar to those of lidocaine, but dissimilar from quinidine, procainamide, and disopyramide.

Tebuzate Absorption

Following oral administration, the bioavailability approaches 100 percent, and is unaffected by food.

Tebuzate side effects and Toxicity

The oral LD50 of tocainide was calculated to be about 800 mg/kg in mice, 1000 mg/kg in rats, and 230 mg/kg in guinea pigs; deaths were usually preceded by convulsions.

Tebuzate Patient Information

Tebuzate Organisms Affected

Humans and other mammals